SunBioInc（A067370）株式概要バイオテクノロジー企業であるサンバイオ社は、ペグ化技術に基づくバイオシミラー医薬品、バイオ医薬品、医療機器の開発、製造、販売を世界中で行っている。 詳細A067370 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析高いレベルの非現金収入 最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( ₩70B )KR市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るA067370 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW497,905 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG497,905 investors already sharing narrativesYour Fair Value₩Current Price₩5.93k936.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture02b2016201920222025202620282031Revenue ₩2.2bEarnings ₩395.1mAdvancedSet Fair ValueView all narrativesSunBio,Inc. 競合他社CytogenSymbol: KOSDAQ:A217330Market cap: ₩69.1bPrestige BioPharmaSymbol: KOSE:A950210Market cap: ₩61.7bCG InvitesSymbol: KOSDAQ:A083790Market cap: ₩65.4bOptipharm.CO.LTDSymbol: KOSDAQ:A153710Market cap: ₩68.2b価格と性能株価の高値、安値、推移の概要SunBioInc過去の株価現在の株価₩5,930.0052週高値₩8,500.0052週安値₩4,840.00ベータ01ヶ月の変化-0.84%3ヶ月変化-1.98%1年変化-15.29%3年間の変化-38.87%5年間の変化-82.94%IPOからの変化-46.42%最新ニュースNew Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (424% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩90.1b market cap, or US$58.6m).お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 24, 2026SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Koreaお知らせ • Mar 25SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million.SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.お知らせ • Mar 07SunBio,Inc., Annual General Meeting, Mar 31, 2025SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m).最新情報をもっと見るRecent updatesNew Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (424% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩90.1b market cap, or US$58.6m).お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 24, 2026SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Koreaお知らせ • Mar 25SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million.SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.お知らせ • Mar 07SunBio,Inc., Annual General Meeting, Mar 31, 2025SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m).お知らせ • Sep 04SunBio,Inc. announced that it expects to receive KRW 5 billion in funding from Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd. and another investorSunBio,Inc. announced a private placement to issue Zero Coupon Series 4 Bearer-Type Interest-Free Unsecured Private Placement Convertible Bonds due September 5, 2029 for the gross proceeds of KRW 5,000,000,000 on September 3, 2024. The transaction will include participation from new investors Synergy IB Win-Win Innovation New Technology Investment Fund KRW 2,500,000,000,Samsung Securities Co., Ltd. (in the fiduciary position of Fund 1) KRW 1,200,000,000, NH Investment & Securities Co., Ltd . (in the fiduciary position of Fund 2) KRW 800,000,000 and Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 3) KRW 500,000,000. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on September 5, 2024. The bonds are 100% convertible into 676,315 shares at a fixed conversion price of KRW 7,393 from September 5, 2025 to August 5, 2029. The bonds bear zero coupon and maturity rate and matures on September 5, 2029.お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 29, 2021SunBio,Inc., Annual General Meeting, Mar 29, 2021, at 11:00 Korea Standard Time.Is New 90 Day High Low • Feb 15New 90-day high: ₩22,000The company is up 140% from its price of ₩9,167 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: ₩17,950The company is up 2.0% from its price of ₩17,650 on 17 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: ₩13,450The company is down 4.0% from its price of ₩13,950 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.株主還元A067370KR BiotechsKR 市場7D-1.0%-9.5%-10.2%1Y-15.3%-11.3%101.8%株主還元を見る業界別リターン: A067370過去 1 年間で-11.3 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A067370は、過去 1 年間で101.8 % のリターンを上げたKR市場を下回りました。価格変動Is A067370's price volatile compared to industry and market?A067370 volatilityA067370 Average Weekly Movement13.8%Biotechs Industry Average Movement11.2%Market Average Movement9.4%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%安定した株価: A067370の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A067370の 週次ボラティリティ は、過去 1 年間で8%から14%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト1997n/an/awww.sunbio.comバイオテクノロジー企業であるサンバイオ社は、ペグ化技術に基づくバイオシミラー、バイオ医薬品、医療機器の開発、製造、販売を世界中で行っている。同社のバイオシミラー製品にはPEG-フィルグラスチム、前臨床段階にあるPEG-EPOとウリカーゼがある。また、ドライマウス症候群治療用医療機器MucoPEG、関節炎膝用粘性サプリメントSynoGELを提供している。前臨床段階のバイオ医薬品候補は脳梗塞と慢性貧血を対象としている。また、PEG誘導体の製造・販売も行っている。同社は1997年に設立され、本社は韓国の軍浦市にある。もっと見るSunBio,Inc. 基礎のまとめSunBioInc の収益と売上を時価総額と比較するとどうか。A067370 基礎統計学時価総額₩69.75b収益（TTM）₩1.39b売上高(TTM)₩2.17b0.0xPER（株価収益率0.0xP/SレシオA067370 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A067370 損益計算書（TTM）収益₩2.17b売上原価₩940.23m売上総利益₩1.23bその他の費用-₩163.57m収益₩1.39b直近の収益報告Dec 31, 2014次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%A067370 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.3%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/15 15:57終値2026/07/15 00:00収益2014/12/31年間収益2014/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SunBio,Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (424% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩90.1b market cap, or US$58.6m).
お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 24, 2026SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea
お知らせ • Mar 25SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million.SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
お知らせ • Mar 07SunBio,Inc., Annual General Meeting, Mar 31, 2025SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).
New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m).
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (424% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩90.1b market cap, or US$58.6m).
お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 24, 2026SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea
お知らせ • Mar 25SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million.SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
お知らせ • Mar 07SunBio,Inc., Annual General Meeting, Mar 31, 2025SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%).
New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m).
お知らせ • Sep 04SunBio,Inc. announced that it expects to receive KRW 5 billion in funding from Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd. and another investorSunBio,Inc. announced a private placement to issue Zero Coupon Series 4 Bearer-Type Interest-Free Unsecured Private Placement Convertible Bonds due September 5, 2029 for the gross proceeds of KRW 5,000,000,000 on September 3, 2024. The transaction will include participation from new investors Synergy IB Win-Win Innovation New Technology Investment Fund KRW 2,500,000,000,Samsung Securities Co., Ltd. (in the fiduciary position of Fund 1) KRW 1,200,000,000, NH Investment & Securities Co., Ltd . (in the fiduciary position of Fund 2) KRW 800,000,000 and Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 3) KRW 500,000,000. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on September 5, 2024. The bonds are 100% convertible into 676,315 shares at a fixed conversion price of KRW 7,393 from September 5, 2025 to August 5, 2029. The bonds bear zero coupon and maturity rate and matures on September 5, 2029.
お知らせ • Mar 10SunBio,Inc., Annual General Meeting, Mar 29, 2021SunBio,Inc., Annual General Meeting, Mar 29, 2021, at 11:00 Korea Standard Time.
Is New 90 Day High Low • Feb 15New 90-day high: ₩22,000The company is up 140% from its price of ₩9,167 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: ₩17,950The company is up 2.0% from its price of ₩17,650 on 17 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: ₩13,450The company is down 4.0% from its price of ₩13,950 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
